通过干细胞决定者Musashi Musashi调节肺癌的发病和进展
Alison G Barber1,2, Cynthia M Quintero1,2,3,4, Michael Hamilton1,2
1Department of Pharmacology and Medicine, University of California San Diego School of Medicine, La Jolla, United States.
eLife
|March 6, 2025
概括
Msi2在肺癌中起着双重作用,促进初始转变和瘤生长. 抑制Msi2显著降低了前临床模型中的瘤负担和延长生存期,将其确定为潜在的治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 干细胞生物学 干细胞生物学
背景情况:
- 肺癌仍然是癌症死亡的主要原因,尽管治疗方面取得了进展.
- 了解肺癌的分子驱动因素,特别是瘤发生过程中重新激活的干细胞程序,至关重要.
- 武士-2 (Msi2) 已涉及各种癌症,但其在肺腺癌中的特定作用需要进一步阐明.
研究的目的:
- 为了研究木沙希-2 (Msi2) 在肺癌发病和进展中的作用.
- 为了确定Msi2是否是肺腺癌的可行的治疗标.
主要方法:
- 在小鼠中利用了广泛的遗传建模,包括Msi记者小鼠和本土Ras/p53驱动的肺癌模型.
- 采用患者衍生异种移植 (PDXs) 来评估Msi2在人类肺癌中的作用.
- 分析了受Msi2表达影响的分子通路.
主要成果:
- Msi2表达使细胞对转化敏感,并驱动瘤的扩散.
- 表达Msi2的细胞表现出一种亲瘤原体的情景,并对瘤原体突变的反应增强 (Ras,p53).
- 在小鼠模型中,Msi2的遗传删除显著降低了瘤负担,延迟了进展,并使中位生存率翻了一番.
- 在患者衍生的异种移植中,Msi2抑制抑制了瘤生长,这表明在人类肺腺癌中保留了依赖性.
- 发现Msi2可以激活关键瘤生长途径,包括肺腺癌中的新型效应因子.
结论:
- Msi2在肺腺癌的侵袭性进展中发挥着关键作用.
- Msi2是治疗肺癌的潜在治疗标.
- 这项研究为肺腺癌的分子生物学提供了新的见解.
相关概念视频
02:40Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
01:01Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
01:21Lineage Commitment
3.0K
Commitment is the process whereby stem cells:
3.0K
02:23Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
01:19Multipotency of Hematopoietic Stem Cells
3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K